PepScribe Launches Telehealth Practice Bringing Clinician-Prescribed, U.S.-Compounded Peptide Therapy to Patients at Home

PepScribe, a telehealth practice connecting patients with U.S.-licensed clinicians for personalized peptide and related therapies, today announced its public launch. The company offers clinician-led online assessments and monthly treatment plans for goals including weight management, hormone health, longevity and cellular health, and recovery.

Consumer interest in peptide therapy has surged, but much of the online supply runs through unlicensed "research chemical" sellers that ship unverified compounds with no prescription, no clinician, and no accountability for what is actually in the vial. PepScribe was built as the opposite of that model: every therapy requires a clinical evaluation by a U.S.-licensed clinician, and every dose is compounded in the United States by a licensed 503A pharmacy. No hidden overseas supply chain.

Getting started takes about three minutes. Patients complete a free online assessment, and a licensed clinician reviews it — typically within 24 hours. If the clinician determines a therapy is appropriate, the prescription is filled by a licensed 503A compounding pharmacy and shipped directly to the patient's home. If it isn't the right fit, the clinician says so, and the patient is never charged. Ongoing care includes asynchronous clinician messaging, lab-driven dose adjustments, and scheduled follow-up reviews.

Peptide therapy grew faster than the infrastructure around it, leaving many patients to buy from anonymous online sellers with no way to know where a compound was made or what it contains. PepScribe was built to remove that uncertainty: every prescription is written by a U.S.-licensed clinician, and every compound comes from a licensed 503A pharmacy in the United States.

At launch, PepScribe's catalog includes compounded semaglutide and tirzepatide for weight management, sermorelin for growth-hormone support, and NAD+ for cellular health, alongside treatments spanning hormone health, sexual health, and hair and skin. The intake is universal: clinicians match patients to therapies based on goals, symptoms, and medical history, and remain the prescriber of record throughout care.

PepScribe is LegitScript-certified, an independent third-party verification of clinician licensure and pharmacy compliance that is required to advertise telehealth services on major platforms. Compounded medications are prepared for individual patients under a clinician's prescription and are not FDA-approved. PepScribe is available in eligible states, with additional states rolling out on an ongoing basis. Patients can check availability and begin a free assessment at pepscribe.com.

About PepScribe

PepScribe is a telehealth practice that connects patients with U.S.-licensed clinicians who evaluate each intake and, when clinically appropriate, prescribe personalized peptide and related therapies for goals including weight management, hormone health, longevity and cellular health, and recovery. Its core offering pairs a clinician-led online assessment with monthly treatment plans — including compounded semaglutide, tirzepatide, sermorelin, and NAD+ — with every dose compounded in the United States by licensed 503A pharmacies and shipped directly to patients' homes. No hidden overseas supply chain. Every assessment is reviewed by a licensed clinician, typically within 24 hours, and patients are not charged unless a treatment is prescribed. Ongoing care includes asynchronous clinician messaging, lab-driven dose adjustments, and scheduled follow-up reviews. Beyond peptide therapy, PepScribe's catalog spans hormone health, sexual health, and hair and skin treatments. PepScribe is LegitScript-certified, an independent third-party verification of clinician licensure and pharmacy compliance. Compounded medications are prepared for individual patients under a clinician's prescription and are not FDA-approved. More information and the full treatment catalog are available at pepscribe.com.

Disclaimer

This press release concerns telehealth services and compounded prescription medications. PepScribe does not manufacture pharmaceuticals or guarantee clinical outcomes. Compounded medications are prescribed only after evaluation by a licensed healthcare provider, are prepared by licensed 503A compounding pharmacies for individual patients, and are not approved by the U.S. Food and Drug Administration (FDA). PepScribe is not affiliated with, endorsed by, or associated with Novo Nordisk (makers of Ozempic® and Wegovy®) or Eli Lilly (makers of Mounjaro® and Zepbound®), and its compounded treatments are not generic equivalents of these branded medications.Availability of services and treatments varies by state and is subject to applicable laws and clinician judgment. Statements regarding potential health, wellness, longevity, weight management, or other therapeutic benefits are provided by the issuer and should not be interpreted as guarantees of efficacy or medical advice. Patients should consult a qualified healthcare provider regarding their individual medical needs.

Media Contact

Media Relations
PepScribe
pepe@pepscribe.com